Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07197307 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study acronym: CLEAR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jan 15, 2030 → Apr 30, 2030
See other at-risk trials from Universität Münster

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv2 Show 6 more changesShow less
    • Primary and study completion pushed from Jan 15, 2030 to Apr 30, 2030
    • Trial sites expanded: 1 → 34 locations
    • Start date changed from estimate of Oct 15, 2025 to Oct 31, 2025
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: 16 to 14
    • Study description expanded, about 43 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Trial Details
NCT Number NCT07197307
Lead Sponsor Universität Münster
Collaborators: AbbVie, Sobi, Inc.
Conditions
(from sponsor)		 Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Related terms Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov